Searched for
SAXAGLIPTIN TABLETS
Stocks in news: Dabur, Grasim, Lupin, RBL Bank, Waaree Renewable TechGrasim Industries said that it will issue shares on a rights basis at Rs 1,812 per share and has set January 10 as the record date.- Glenmark gets USFDA nod to market generic diabetes drugThe company has received final approval from the US Food & Drug Administration (US FDA) for Saxagliptin Tablets (2.5 mg and 5 mg), the gene...
- Glenmark gets USFDA nod for generic diabetes drugGlenmark Pharmaceuticals Inc, USA, a unit of the company, has received tentative approval from the US Food & Drug Administration (US FDA) f...
- Glenmark Pharma gets tentative USFDA nod for generic anti-diabetes tabletsGlenmark Pharmaceuticals on Wednesday said it has received tentative approval from the US health regulator for its generic Dapagliflozin an...
- USV in talks with Novartis to buy Jalra Trademark for Rs. 200 CroreMumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from Novartis for a deal...
- Glenmark gets USFDA's tentative nod for Saxagliptin tabletsAccording to IMS Health sales data for the 12-month period ending April 2017, the Onglyza tablets, 2.5 mg and 5 mg market achieved annual s...
- India rejects compulsory license application of Lee Pharma against AstraZeneca’s SaxagliptinThe Indian Patent Office has rejected the application of Lee Pharma for a compulsory license on AstraZeneca’s anti-diabetes drug saxaglipti...
- India rejects Lee Pharma’s compulsory licence pleaIndia has decided against giving the compulsory licence for Anglo-Swedish drugmaker AstraZeneca’s key antidiabetes compound Saxagliptin.
- High Court rejects AstraZeneca’s diabetes drug pleaThe Delhi High Court has dismissed AstraZeneca’s plea to block Hyderabadbased Lee Pharma from making copies of its anti-diabetes drug Ongly...
- Lee Pharma wants licence for AstraZeneca's diabetes drugLee Pharma filed the application on June 29 to make a generic version of the patented drug, marketed as Onglyza, under Section 84 of the Pa...
Load More
